文献速递贫血与红细胞疾病

鼻内、肌注与静脉维生素B12治疗贫血血液学恢复比较

Comparative Efficacy of Intranasal, Intramuscular, and Intravenous Vitamin B12 Therapy for Hematological Recovery in Vitamin B12 Deficiency Anemia: A Randomized Controlled Trial.
PubMed 文献 · Am J Hematol · 2026-07-02

一项随机对照试验纳入153例维生素B12缺乏性贫血成人,比较鼻内、静脉与肌注维生素B12的血液学恢复。三种途径均显著改善血红蛋白,调整协变量后组间无显著差异;基线Hb、纯素饮食和年龄为独立预测因素,鼻内途径为安全非侵入性替代。

要点

  • 三种途径28天均显著提升Hb,调整后组间无差异。
  • 肌注组网织红细胞反应最强,肠外途径LDH正常化更优。
  • 鼻内维生素B12安全有效,适合长期维持和资源有限环境。

核心结论

  • 鼻内、静脉与肌注维生素B12在28天均产生显著血液学恢复,调整协变量后组间无统计学显著差异。

研究设计与样本

  • 前瞻性随机对照试验,纳入153例维生素B12缺乏成人,随机分为鼻内组55例、静脉组56例、肌注组42例。

主要发现

  • 鼻内、静脉、肌注组平均ΔHb分别为+2.48、+1.80、+2.18 g/dL,组内均p<0.001。
  • 未调整分析组间差异H=7.23,p=0.027,但ANCOVA后所有p>0.06。
  • MCV下降组间等效(Kruskal-Wallis p=0.948)。
  • LDH正常化肠外途径更优(H=8.17,p=0.017);肌注组网织红细胞增多最明显(H=13.93,p=0.001)。
  • 多变量回归(adj. R²=0.575)中基线Hb(β=-0.298,p<0.001)、纯素饮食(β=+1.30,p=0.001)、年龄(β=-0.013/年,p=0.039)为独立预测因素,途径非预测因素。

临床怎么用

  • 鼻内维生素B12可作为安全、有效、非侵入性替代方案,适用于长期维持治疗和资源有限环境。

局限性

  • 所有结论仅限于短期血液学结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Vitamin B12 deficiency causes megaloblastic anemia and ineffective hematopoiesis. While intramuscular administration remains standard, intravenous and intranasal alternatives are increasingly used. Rigorous comparative data on hematological efficacy across routes remain limited. We thus aimed to compare intranasal, intramuscular, and intravenous vitamin B12 therapy for hematological recovery in vitamin B12 deficiency anemia, and to identify independent predictors of treatment response. In this prospective randomized controlled trial (IEC/2024/450; CTRI/2024/10/075521), 153 adults with vitamin B12 deficiency were randomized to intranasal (n = 55), intravenous (n = 56), or intramuscular (n = 42) administration. Hemoglobin (Hb), mean corpuscular volume (MCV), reticulocyte count, and lactate dehydrogenase (LDH) were assessed at baseline and on Days 7, 14, and 28. Inter-group comparisons used the Kruskal-Wallis test; covariate-adjusted analyzes employed ANCOVA and multiple linear regression. All three routes produced significant hematological recovery (all within-group p < 0.001). Mean ΔHb was +2.48, +1.80, and +2.18 g/dL for intranasal, intravenous, and intramuscular groups. Although the unadjusted analysis detected an intergroup difference (H = 7.23, p = 0.027), ANCOVA abolished the significance (all p > 0.06). MCV reduction was equivalent (Kruskal-Wallis p = 0.948). LDH normalization was greater with parenteral routes (H = 8.17, p = 0.017); intramuscular therapy produced the most pronounced reticulocytosis (H = 13.93, p = 0.001). In multivariate regression (adj. R 2 = 0.575), baseline Hb (β = -0.298, p < 0.001), vegan diet (β = +1.30, p = 0.001), and age (β = -0.013/year, p = 0.039) were independent predictors; route was not. All three routes produce hemoglobin recovery at 28 days with no statistically significant adjusted differences. Intranasal vitamin B12 is a safe, effective, noninvasive alternative suitable for long-term maintenance and resource-limited settings. All conclusions are restricted to short-term hematological outcomes. Trial Registration: CTRI/2024/10/075521.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Singh SK, Arora R, Pramanik SK, et al. Comparative Efficacy of Intranasal, Intramuscular, and Intravenous Vitamin B12 Therapy for Hematological Recovery in Vitamin B12 Deficiency Anemia: A Randomized Controlled Trial. Am J Hematol. 2026. PMID: 42393020. doi:10.1002/ajh.70433

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。